Dataset Information

Effect of CDK7 inhibitor, FHD-286, SNDX-50469, or Tasquinimod on protein expression alterations in patient-derived secondary AML or de novo MLL1-rearranged AML cells

ABSTRACT: Patient-derived secondary AML cells were treated with 100 nM of SY-5609 for 24 hours, 100 nM of FHD-286 for 48 hours, or 20 µM of Tasquinimod for 48 hours to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitory and lethal effects of treatment with a CDK7 inhibitor, chromatin remodeling inhibitor, or S100A8/S100A9 inhibitor or in secondary AML cells. Patient-derived de novo AML cells with MLL1 rearrangement and Menin T349M mutation were treated with 100 nM of FHD-286 or 500 nM SNDX-50469 for 48 hours to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitory and/or lethal effects of treatment with a chromatin remodeling inhibitor, FHD-286, or a Menin inhibitor SNDX-50469 in MLL1 rearranged AML cells

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Antrix Jain

LAB HEAD: Kapil N. Bhalla

PROVIDER: PXD053548 | Pride | 2025-04-28

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	52917_1_EXP_1067_hs_TMT16_prof_250ng_F01.pepXML	Pepxml
	52917_1_EXP_1067_hs_TMT16_prof_250ng_F01.raw	Raw
	52917_1_EXP_1067_hs_TMT16_prof_250ng_F02.pepXML	Pepxml
	52917_1_EXP_1067_hs_TMT16_prof_250ng_F02.raw	Raw
	52917_1_EXP_1067_hs_TMT16_prof_250ng_F03.pepXML	Pepxml

Items per page:

1 - 5 of 50

Publications

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML.

Fiskus Warren W Mill Christopher P CP Bose Prithviraj P Masarova Lucia L Pemmaraju Naveen N Dunbar Andrew A Birdwell Christine E CE Davis John A JA Das Kaberi K Hou Hanxi H Manshouri Taghi T Jain Antrix A Malovannaya Anna A Philip Kevin K Alhamadani Noor N Matthews Alicia A Lin Katie K Flores Lauren B LB Loghavi Sanam S DiNardo Courtney C Su Xiaoping X Rampal Raajit K RK Bhalla Kapil N KN

Blood 20250201 6

<h4>Abstract</h4>Rising blast percentage or secondary acute myeloid leukemia (sAML) transformation in myeloproliferative neoplasms (MPNs) leads to JAK1/2 inhibitor (JAKi) therapy resistance and poor survival. Here, we demonstrate that treatment with the CDK7 inhibitor (CDK7i) SY-5609 depletes phenotypically characterized post-MPN sAML stem/progenitor cells. In cultured post-MPN sAML SET2, HEL and patient-derived (PD) post-MPN sAML cells, SY-5609 treatment inhibited growth and induced lethality w ...[more]

PMID: 39561280

Dataset Information

Effect of CDK7 inhibitor, FHD-286, SNDX-50469, or Tasquinimod on protein expression alterations in patient-derived secondary AML or de novo MLL1-rearranged AML cells

Dataset's files

Publications

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Similar Datasets

Project title: Effect of FHD-286 or BRG1/BRM degrader AU15330 on protein expressions in MLL1-rearranged AML cells
2025-04-28 | PXD055994 | Pride

Determination of protein expression changes due to treatment with chromatin remodeling inhibitor FHD-286 in MLL1-rearranged AML cells
2025-05-26 | PXD047965 | Pride

Determination of protein expression changes due to treatment with chromatin remodeling inhibitor FHD-286 in patient-derived mutant NPM1 and FLT-ITD-expressing AML cells
2025-05-06 | PXD047967 | Pride

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor (ChIP-Seq)
2024-03-01 | GSE252935 | GEO

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor (Bulk ATAC-Seq)
2024-03-01 | GSE252933 | GEO

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor (scATAC-Seq)
2024-03-01 | GSE252936 | GEO

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor (scRNA-Seq)
2024-03-01 | GSE252937 | GEO

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor (Bulk RNA-Seq)
2024-03-01 | GSE252934 | GEO

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
2022-03-12 | GSE190719 | GEO

A novel Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia
2019-02-28 | GSE127298 | GEO